Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: Indiana University
Published in: "Business Horizons", 2005

Abstract

Ronald W Dollens recently retired from the positions of CEO (Chief Executive Officer) and President of Guidant Corp, an Indianapolis-based medical technology manufacturer. Dollens was appointed CEO and President of Guidant when the company was formed as a split-off of Eli Lilly and Co in 1994. During his 10 years of leadership at Guidant, the firm grew at an average of 18% per year, from just under $900 million in sales in 1994 to $3.7 billion in 2003. Today, Guidant employs more than 12,000 and is an industry leader in cardiovascular technology.

About

Abstract

Ronald W Dollens recently retired from the positions of CEO (Chief Executive Officer) and President of Guidant Corp, an Indianapolis-based medical technology manufacturer. Dollens was appointed CEO and President of Guidant when the company was formed as a split-off of Eli Lilly and Co in 1994. During his 10 years of leadership at Guidant, the firm grew at an average of 18% per year, from just under $900 million in sales in 1994 to $3.7 billion in 2003. Today, Guidant employs more than 12,000 and is an industry leader in cardiovascular technology.

Related